Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurbinectedin + Avelumab Maintenance in mUC
NCT05574504Phase 2Withdrawn
- Sponsor
- AdventHealth
- Start
- May 2023
- Primary completion
- Nov 2026
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lurbinectedin in urothelial carcinoma (UC), sponsored by AdventHealth. Primary endpoint: Progression-Free Survival at 32 months. Planned start May 2023; status: withdrawn.
02
Drugs
lurbinectedin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05574504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574504.